
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Selling, General & Administrative
LAVA Therapeutics NV
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Selling, General & Administrative
-$12.7m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Selling, General & Administrative
-$189.4m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-50%
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Selling, General & Administrative
-€13.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-7%
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Selling, General & Administrative
-$51.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
![]() |
argenx SE
XBRU:ARGX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
-77%
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Selling, General & Administrative
-$82.8m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Selling, General & Administrative?
Selling, General & Administrative
-12.7m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Selling, General & Administrative amounts to -12.7m USD.
What is LAVA Therapeutics NV's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-67%
Over the last year, the Selling, General & Administrative growth was 10%. The average annual Selling, General & Administrative growth rates for LAVA Therapeutics NV have been -67% over the past three years .